| 产品描述: | 缺口抑制剂;Notch Inhibitors;;InformationCB-103 CB-103 is an orally active inhibitor of the Notch transcription activation complex. CB-103 produces Notch loss-of-function phenotypes in flies and mice and inhibits the growth of human breast cancer and leukemia xenografts.TargetsNotchIn vitroCB-103 inhibits growth of Notch-addicted human T cell acute lymphoblastic leukemia cell lines through modulation of the Notch transcription complex.In vivoCB-103 function in vivo recapitulates genetic notch loss-of-function phenotypes without causing gut toxicity. CB-103 blocks tumor growth of GSI-resistant cancers.Cell Research(from reference)Cell lines:marrow mesenchymal stroma cells (MSCs), RPMI-8402 cells Concentrations:10 nM to 25 μM, 1 μM Incubation Time:3 days, 1 h, 4 h, 24 h |
| 靶点: |
notch signaling pathway |
| 体内研究: |
Limantrafin 抑制小鼠中依赖 NOTCH 的细胞过程。
Limantrafin 阻止 T-ALL 的 PDX 模型在体内的生长。
Limantrafin(25 mg/kg;腹腔注射/口服;每天 2 次;持续 2 周)抑制 GSI/Mab 耐药的三阴性乳腺癌的生长。
Limantrafin 在人类 T-ALL 和小鼠乳腺肿瘤的异种移植模型中表现出抗肿瘤活性。 |
| 参考文献: |
1. Freddy Radtke, et al. Inhibitors of notch signalling pathway and use thereof in treatment of cancers. US9296682B2.2. R.Lehal, et al. Development of a novel first-in-class oral inhibitor of the NOTCH pathway.3. Rajwinder Lehal, et al. Non clinical pharmacology, pharmacokinetics and safety profiling of CB-103: A novel first-in-class small molecule inhibitor of the NOTCH pathway.4. Jose Manuel Perez Garcia, et al. First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
4.127 ml |
20.634 ml |
41.268 ml |
| 5 mM |
0.825 ml |
4.127 ml |
8.254 ml |
| 10 mM |
0.413 ml |
2.063 ml |
4.127 ml |
| 50 mM |
0.083 ml |
0.413 ml |
0.825 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |